Frelii Inc. announced the details of its recent agreement with Orn Health Inc. to license the Frelii exome and whole genome sequencing and artificial intelligence (AI) technology for use with new franchisee partners in their own medical practices for enhancing patient treatment resources. Currently, Frelii provides a consumer-level DNA Kit Package™ and report with alignment specifically for OTC cannabis, CBD, supplements and nutraceuticals that can be disseminated directly to a consumer without the presence of a physician or licensed healthcare provider. Frelii has forged this partnership with Orn to create broader opportunities for the company within the medical and healthcare industries, specifically. Now they will be able to offer their more enhanced Medical Grade DNA Kit Package™ and report, inclusive of specific panels that can be selected only by a licensed physician or healthcare provider.